KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to $163.6 million.

  • Alnylam Pharmaceuticals' Cash from Operations rose 27277.79% to $163.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $524.1 million, marking a year-over-year increase of 640510.11%. This contributed to the annual value of $524.1 million for FY2025, which is 640510.11% up from last year.
  • Alnylam Pharmaceuticals' Cash from Operations amounted to $163.6 million in Q4 2025, which was up 27277.79% from $325.1 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Cash from Operations registered a high of $359.4 million during Q3 2023, and its lowest value of -$235.7 million during Q1 2021.
  • For the 5-year period, Alnylam Pharmaceuticals' Cash from Operations averaged around -$28.2 million, with its median value being -$105.0 million (2022).
  • In the last 5 years, Alnylam Pharmaceuticals' Cash from Operations plummeted by 21771.1% in 2024 and then skyrocketed by 64383.74% in 2025.
  • Alnylam Pharmaceuticals' Cash from Operations (Quarter) stood at -$150.1 million in 2021, then rose by 12.1% to -$132.0 million in 2022, then surged by 77.42% to -$29.8 million in 2023, then tumbled by 217.71% to -$94.7 million in 2024, then surged by 272.78% to $163.6 million in 2025.
  • Its Cash from Operations was $163.6 million in Q4 2025, compared to $325.1 million in Q3 2025 and $153.7 million in Q2 2025.